Drugs / AT2221
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02675465 | Apr 2016 → Aug 2024 | glycogen storage disease II | Amicus Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04138277 | Dec 2019 → Dec 2024 | glycogen storage disease due to acid maltase deficiency, late-onset | Amicus Therapeutics | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03865836 | — | glycogen storage disease II | Amicus Therapeutics | Available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04327973 Background | — | glycogen storage disease due to acid maltase deficiency, infantile onset | Amicus Therapeutics | Available | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-10-02 | BioMarin Pharmaceutical | BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress biomarin.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT2221 | “Participants received ATB200 co-administered with AT2221 capsule (Miglustat)” NCT04327973 ↗ |
| Known as | Miglustat | “Participants received ATB200 co-administered with AT2221 capsule (Miglustat)” NCT04327973 ↗ |
| Route | Oral | “First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221” NCT02675465 ↗ |